Central European Journal of Medicine

, Volume 7, Issue 6, pp 691–699 | Cite as

The basis of the discovery process for a new pharmaceutical product

  • Veselin Dickov
Review Article


The basis of the discovery process for a new pharmaceutical product is in understanding the mechanism of action of a particular disease or processes in the organism related to the disease and/or its symptoms. The essence of a pharmaceutical is in the active ingredient capable of affecting processes within the organism beneficially. The discovery process includes a particular sequence of activities of various profiles of experts, about which various authors agree. The history of pharmaceutical industry (and pharmacy) is measured from one discovery of an innovative drug or approach to treatment of a particular disease to the next one. The cost of pharmaceutical products is one of the key causes of controversy related to this industry. Numerous cultures have proverbs expressing the opinion that health is priceless or that health is the greatest wealth. What if health does have a price? One of the basic premises of marketing is that price should reflect consumer value.


Pharmaceutical market New drug development Pricing regulations The cost of pharmaceutical products 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Dickov V., Kuzman B. (2011) ”Analyzing Pharmaceutical Industry” National Journal of Physiology, Pharmacy and Pharmacology. NJPPP.; 1(1): pp. 1–8Google Scholar
  2. [2]
    Suhrcke M, McKee M, Sauto Arce R. Tsolova S. and Mortensen J. (2005): The contribution of health to the economy in the European Union. European Commission. Office for Official Publications of the European Communities. Luxembourg, No 3, pp. 373–377Google Scholar
  3. [3]
    Dickov V. Dickov A. Milicevic B., (2010) “Freedom from disease — Health protection system in Serbia — management approach”, International Journal, Total Quality Management & Excellence, Vol. 38, No. 2, pp.119–126Google Scholar
  4. [4]
    Franklin J. Carter, Ravindra Chitturi, Segmentation Based on Physicians Behavior(2009): Implications for Sales forecasting and Marketing-mix Strategy; Journal of Personal Selling & Sales Management, Vol.XXIX, No. 1, pp. 123–134Google Scholar
  5. [5]
    Gagan Bhalla, Theodoros Evgeniou, Leonard Lerer, (2004) Customer Relationship Management and Networked Healthcare in the Pharmaceutical Industry; International Journal of Medical Marketing, Vol.4, pp. 34–35CrossRefGoogle Scholar
  6. [6]
    Gregory T. Gundlach, (2007) The American Marketing Association’s 2004 Definition of marketing: perspectives on Its Implications for Scholarship and the Role and Responsibility of marketing in Society; Journal of Public Policy & Marketing, Fall, Vol. 26(2). pp. 234–245Google Scholar
  7. [7]
    Jennz Darroch, Morgan P. Miles, Andrew Jardine, Ernest F. Cooke, (2004) The AMA Definition of Marketing and its Relationship to a Market Orientation: An Extension of Cooke, Rayburn, & Abercrombie; Journal of Marketing Theory and Practice Fall, No 1, pp. 12–15Google Scholar
  8. [8]
    Dickov V., Nerandjic B.and Perovic V: (2004) “Ekonomika moderna” Stilos, FTN, Novi Sad 2004. Vol 1, No 1, pp. 9–23Google Scholar
  9. [9]
    Sandier S., et al: (2004) Health Care Systems in Transition, Edited by: Sarah Thomson and Elias Mossialos, WHO — Regional Office for Europe, No 1, pp.45–51Google Scholar
  10. [10]
    Alfred D. Chandler Jr., (2005) Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries; Harvard University Press, London, UK, Vol.1, No 1, pp. 36–39Google Scholar
  11. [11]
    Fran Hawthorne, (2005) Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat; John Wiley & Sons, Inc., Hoboken, New Jersey, USA Vol.3 No 3, pp. 56–67Google Scholar
  12. [12]
    Frank Bradley, (2009) Strategic Marketing In the Customer Driven Organization; John Wiley and Sons, Chichester, West Sussex, England, No. 3, pp. 89–90Google Scholar
  13. [13]
    Dickov V., Kuzman B. “The Promotion of Pharmaceutical Products”, Materia Socio Medica 2011. Volume 23. Number 1. Pp. 48–59Google Scholar
  14. [14]
    Henry Mintzberg, James Brian Quinn, Sumantra Ghoshal, (2010) The Strategy Process; Prentice Hall Europe, Hertfordshire, UK, No. 1, pp.76–78Google Scholar
  15. [15]
    Kate Gillespie, Jeannet Jean-Pierre, Hennessey H. David, (2009) Global Marketing; Houghton Mifflin Company, Boston, USA, Vol. 1, No 3, pp. 60–62Google Scholar
  16. [16]
    Emira Kahrovic “Chemical feature of inorganic compounds as anticancer agents” HealthMED — Volume 5. Number 5. 2011. pp.1112–1117Google Scholar
  17. [17]
    Dickov A., Vuckovic N., Dickov V., S. Martinović- Mitrović “Post traumatic stress disorder (PTSD) after traffic accident — PTSD and traffic accidents”. HealthMED — Volume 4/Number 4/Supplement 1/2010. pp.1037–1043Google Scholar
  18. [18]
    Orville C. Walker Jr., Harper W. Boyd Jr., John Mullins, Jean-Claude Larreche, (2010) Marketing Strategy: A Decision-Focused Approach; McGraw-Hill Irwin, New York, Vol.1, pp. 223–229Google Scholar
  19. [19]
    Robert F. Dyer, Ernest H. Forman, An Analitic Approach to Marketing Decisions; Prentice Hall, New Yersey, USA, 1991. pp.107–110Google Scholar
  20. [20]
    Dickov V., Mitrovic D., Kuzman B., HEALTHY IN TRANSITION — Private or government health institutions — Patient choice,, Case Study Case Rep. 2011; 1 pp. 61–73Google Scholar
  21. [21]
    Tom Blackett, Rebecca Robins, Brand Medicine, The Role of Branding in the Pharmaceutical Industry; Palgrave, New York, USA, 2002 pp.98–103Google Scholar
  22. [22]
    William O. Bearden, Thomas N. Ingram, Raymond W. Longest J.B. Rakich J.S. and Darr K. Managing: Health Service Organization and Systems, London (1993) pp. 234–256Google Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Faculty of International ManagementEuropean UniversityBelgradeSerbia

Personalised recommendations